Third-Party Review Could Help Revive OTC Monograph Process, Attorney Says
This article was originally published in The Tan Sheet
Executive Summary
Outside party review of OTC drugs for monograph approval could help renew an industry that is "stagnating," Akin, Gump, Strauss, Hauer & Feld attorney Robert Pinco suggested at a Drug Information Association conference on "OTCness" in Washington, D.C. Sept. 16-17.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning